Carroll Brendan T, Surber Susan A
Dr. Carroll is Associate Professor of Psychiatry (Volunteer), University of Cincinnati, College of Medicine, and Chief, Psychiatry Service, MHCL, Chillicothe VAMC, Chillicothe, OH.
Psychiatry (Edgmont). 2009 Jul;6(7):45-7.
Neuroleptic malignant syndrome is a serious and potentially fatal adverse effect of antipsychotic medications. Although diagnostic criteria for neuroleptic malignant syndrome have been established and are widely accepted and used, it should be recognized that atypical presentations occur, particularly during treatment with atypical antipsychotics. However, it remains unclear whether these atypical presentations represent early or impending neuroleptic malignant syndrome. Furthermore, since neuroleptic malignant syndrome is a diagnosis of exclusion, careful consideration of other neuropsychiatric conditions should occur. Relying on creatine phosphokinase elevation may result in an incorrect diagnosis of atypical neuroleptic malignant syndrome. We wish to present a case of this diagnostic dilemma in a patient with catatonia.
抗精神病药物恶性综合征是抗精神病药物一种严重且可能致命的不良反应。尽管抗精神病药物恶性综合征的诊断标准已经确立并被广泛接受和应用,但应当认识到非典型表现也会出现,尤其是在使用非典型抗精神病药物治疗期间。然而,这些非典型表现是否代表早期或即将发生的抗精神病药物恶性综合征仍不清楚。此外,由于抗精神病药物恶性综合征是一种排除性诊断,因此应仔细考虑其他神经精神疾病。依赖肌酸磷酸激酶升高可能会导致非典型抗精神病药物恶性综合征的误诊。我们希望介绍一例紧张症患者的这种诊断困境。